NASDAQ · ALKS

Alkermes Inc.. PLC

$52.73 -$0.16 (-0.30%) 1D After hours
Charting by TradingView

Key Metrics

$8.82B
Market cap
57.72×
P/E · TTM
$1.56B
Revenue · TTM
$152.72M
Net income
EPS · TTM $0.91
Dividend yield —
Free cash flow $221.80M
Beta · 1Y 0.72
EBITDA · TTM $243.21M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 31
    The stock moved +17.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$8.82B
Enterprise value$9.79B
Shares outstanding166.7M
52-wk range$25.17 – $55.67
Avg volume · 20D1.7M
Net cash −$972.11M
Book value / share$10.38
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Alkermes Inc.. PLC
IPO dateJul 16, 1991
Employees2050

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E57.72
P/S5.64
P/FCF39.75
EV/EBITDA40.24
EV/Sales6.26
Graham №$14.54

Profitability

Gross —
Operating 13.1%
Net 9.8%
FCF 14.2%
ROE / ROIC 9.5% · 5.6%

Financial Health

Current ratio2.27
Quick ratio1.70
Debt / equity0.86
Debt / EBITDA 6.21
Net cash −$972.11M
Working capital$759.15M

Cash Flow · TTM

Operating CF $256.20M
Capex −$34.40M
Free cash flow $221.80M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

2.6
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$14.54 vs $52.73
Trades 3.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings